Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The evolving role of futibatinib for advanced cholangiocarcinoma.

Expert review of gastroenterology & hepatology - 1 Apr 2026

Persano Mara, Casadei-Gardini Andrea, Camera Silvia, Rimini Margherita

Abstract excerpt

INTRODUCTION: Cholangiocarcinoma (CCA) continues to be classified as a rare cancer with high mortality rates, underscoring the urgent need for more effective systemic treatment strategies. The widespread implementation of next-generation sequencing has enabled comprehensive characterization of the genomic landscape of CCA, revealing a relatively high prevalence of actionable genetic alterations. AREAS COVERED: In...

Topics

Join the communities discussing this publication.

Pyrimidines
Bile Duct Neoplasms
Cholangiocarcinoma
Drug Resistance, Neoplasm
Protein Kinase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Receptor, Fibroblast Growth Factor, Type 2

Source

Identifiers

PMID: 41869869
DOI: 10.1080/17474124.2026.2649804

Genes

FGFR2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The evolving role of futibatinib for advanced cholangiocarcinoma.PMID 41869869Read ↗

FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.Semantic proximity Read ↗

Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy.Semantic proximity Read ↗

Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications.Semantic proximity Read ↗

FGFR2 Inhibition in Cholangiocarcinoma.Semantic proximity Read ↗

Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma.Semantic proximity Read ↗

Molecular mechanisms and genetic features of cholangiocarcinoma: implications for targeted therapeutic strategiesSemantic proximity Read ↗

Precision Oncology in Cholangiocarcinoma: Two Fusion-Positive Case Reports and a Literature ReviewSemantic proximity Read ↗

Molecular biology of cholangiocarcinoma and its implications for targeted therapy in patient management.Semantic proximity Read ↗

A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma.Semantic proximity Read ↗

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements.Semantic proximity Read ↗

Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology.Semantic proximity Read ↗

Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.